Faculty Collaboration Database

Nanomedicines for dysfunctional macrophage-associated diseases. J Control Release 2017 Feb 10;247:106-126

Date

01/07/2017

Pubmed ID

28057522

Pubmed Central ID

PMC5360184

DOI

10.1016/j.jconrel.2016.12.032

Scopus ID

2-s2.0-85008877575 (requires institutional sign-in at Scopus site)   47 Citations

Abstract

Macrophages play vital functions in host inflammatory reaction, tissue repair, homeostasis and immunity. Dysfunctional macrophages have significant pathophysiological impacts on diseases such as cancer, inflammatory diseases (rheumatoid arthritis and inflammatory bowel disease), metabolic diseases (atherosclerosis, diabetes and obesity) and major infections like human immunodeficiency virus infection. In view of this common etiology in these diseases, targeting the recruitment, activation and regulation of dysfunctional macrophages represents a promising therapeutic strategy. With the advancement of nanotechnology, development of nanomedicines to efficiently target dysfunctional macrophages can strengthen the effectiveness of therapeutics and improve clinical outcomes. This review discusses the specific roles of dysfunctional macrophages in various diseases and summarizes the latest advances in nanomedicine-based therapeutics and theranostics for treating diseases associated with dysfunctional macrophages.

Author List

He H, Ghosh S, Yang H

Author

Hu Yang PhD Chair, Professor in the Biomedical Engineering department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Acquired Immunodeficiency Syndrome
Animals
Arthritis, Rheumatoid
Atherosclerosis
Diabetes Mellitus, Type 2
Drug Delivery Systems
Humans
Inflammation
Inflammatory Bowel Diseases
Macrophages
Nanomedicine
Neoplasms
Obesity